… control and EFS were strongly correlated with those on overall survival (R=0·94 and 0·98, …
overall survival were stronger than those between locoregional control and overall survival (…

Purpose Progression-free survival (PFS) has previously been established as a surrogate for
overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC …

… A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years
… Individual patient data were pooled from 18 randomized phase III colon cancer adjuvant …

… endpoints and overall survival at individual and trial levels. … DFS and overall survival were
very good at the individual level … and overall survival were very good at the individual level (ρ 2 …

… progression-free survival and overall survival in patients with BRAF V600 -mutant melanoma,
although the degree of treatment benefit varied. Studies of small groups of patients treated …

… to determine the pooled overall treatment effect on OS of … patients with newly diagnosed
EGFR-mutated advanced NSCLC using individual patient data from RCTs with updated survival …

… in patients with non-small cell lung cancer (NSCLC). We examined whether progression-free
survival (PFS), post-progression survival (… NSCLC by using individual-level data, given the …

Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR)
in node-negative, estrogen receptor (ER)–positive breast cancer. We evaluated the …

… PFS and OS for individual trial arms. Seven studies used individual patient data to examine
the relationship between PFS and OS for individual patients. Thirteen studies examined the …

… survival has been inconclusive. To evaluate the effect of MR on overall survival according to
patient … certain adverse events, we performed an individual patient data (IPD) meta-analysis. …